Obsessive-compulsive symptoms appear to frequently occur among schizophrenic patients receiving treatment with clozapine, and these symptoms exert a negative effect on the patients’ wellbeing, a study reports.
The orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α (HIF-1α) GB004 appears to improve disease activity in patients with ulcerative colitis, with the drug being well-tolerated, according to the results of a phase Ib trial.
The risk for hip fracture slightly increases following osteoporosis drug holidays after long-term therapy with risedronate compared with alendronate, a study has found, adding that future research must examine how best to lessen such risk.
Treatment with percutaneous ethanol injection (PEI) appears to produce marked reductions in the volume of benign cystic thyroid nodules, with the reduction evident at 6 months post-treatment and stable over time, according to the results of a meta-analysis.
The orally bioavailable, investigational neuroactive steroid zuranolone appears to be beneficial in the treatment of insomnia, producing improvements in sleep measures, including sleep efficiency, duration of awakenings, and total sleep time in adults, according to the results of a phase I study.
An already elevated serum uric acid level at baseline and achievement of high steady-state serum favipiravir concentrations during therapy contribute to an increased risk of developing treatment-induced hyperuricaemia, according to a study.